 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| Lexette (halobetasol propionate foam) / Mayne Pharma
FDA event: $MYPHY FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis https://t.co/EU9vY4g7iS (Twitter) - Sep 21, 2021
- Lexette (halobetasol propionate foam) / Mayne Pharma
[VIRTUAL] Mayne Pharma_Evaluaiton of Adrenal Suppression Potential of Halobetasol Foam in Adolescent Patients with Plaque Psoriasis_Hebert et al. 2020 () - Jun 23, 2021 - Abstract #SDDS2021SDDS_93;
- | Sorilux (calcipotriene foam) / Mayne Pharma, Lexette (halobetasol propionate foam) / Mayne Pharma
New P4 trial: Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis (clinicaltrials.gov) - Sep 29, 2020
P4, N=30, Not yet recruiting, Sponsor: Skin Sciences, PLLC
- Lexette (halobetasol propionate foam) / Mayne Pharma
Trial completion, Trial primary completion date: Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis (clinicaltrials.gov) - Jan 15, 2020
P4, N=23, Completed, Sponsor: Mayne Pharma International Pty Ltd
Recruiting --> Completed | Trial primary completion date: Sep 2019 --> Dec 2019
- | Lexette (halobetasol propionate foam) / Mayne Pharma
New P4 trial: Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis (clinicaltrials.gov) - Jun 19, 2019
P4, N=25, Recruiting, Sponsor: Mayne Pharma International Pty Ltd
- ||| Lexette (halobetasol propionate foam) / Mayne Pharma
Lexette, a topical corticosteroid foam, has received trade name approval to treat #psoriasis. https://t.co/YRbbEPzYag (Twitter) - May 6, 2019